Decision · EU
Council Decision (EU) 2026/1070 of 5 May 2026 on the position to be taken on behalf of the European Union within the CETA Joint Committee established under the Comprehensive Economic and Trade Agreement (CETA) between Canada, of the one part, and the European Union and its Member States, of the other part, as regards the inclusion of active pharmaceutical ingredients as medicinal products or drugs listed in paragraph 2 of Annex 1 to the Protocol on the mutual recognition of the compliance and enforcement programme regarding good manufacturing practices for pharmaceutical products
- Identifier
- CELEX 32026D1070
- Status
- in_force
- Adopted
- 5 May 2026
- Published
- 5 May 2026
- Language
- en
- Official source
- https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32026D1070
- Source provider
- eurlex
- Retrieved
- 2026-08-26T22:55:22.463Z
Identifier
- CELEX: 32026D1070 · eurlex
Direct relationships
PoliticalRepo: CELEX 32026D1070
- Identifier matchPROJECTS_FROM
Same CELEX 32026D1070 projected from PoliticalRepo EUR-Lex row 32026D1070.
LegalInstrument → PoliticalRecord · Open related record
- Identifier matchIDENTIFIER_MATCH
Shared official identifier CELEX=32026D1070.
LegalInstrument → PoliticalRecord · Open related record